check_circleStudy Completed

Atrial Fibrillation

Bayer Identifier:

18491

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Registry study of adherence to treatment with rivaroxaban and warfarin in patients with atrial fibrillation, as requested by the Dental and Pharmaceutical Benefits Board (TLV)

Trial purpose

This is a retrospective registry study to describe and compare the adherence among AF patients initiating treatment with rivaroxaban (without previous warfarin or NOAC use) with those initiating treatment with warfarin (with and without previous warfarin or NOAC use). It is a requirement by The Dental and Pharmaceutical Benefits Board (TLV) in Sweden to provide data on a comparison of adherence to NOAC treatment vs. warfarin for newly treated patients in atrial fibrillation. Several Swedish registries will be utilized.

Key Participants Requirements

Sex

Both

Age

18 - 120 Years
  • -

  • -

Trial summary

Enrollment Goal
57558
Trial Dates
October 2015 - November 2015
Phase
N/A
Could I Receive a placebo
N/A
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Sweden

Trial design

Registry study of adherence to treatment with rivaroxaban and warfarin in patients with atrial fibrillation, as requested by the Dental and Pharmaceutical Benefits Board (TLV)
Trial Type
Observational
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.